Archive for the ‘hepatology’ Category
A former postdoc at the National Institutes of Health (NIH) committed misconduct in a study of hepatitis by falsely claiming that data from a single trial subject were actually from more than a dozen different people, the Office of Research Integrity (ORI) has found.
The investigation was prompted by allegations made by readers of the paper. Baoyan Xu made what the ORI called “a limited admission” that “some better looking strips were repeatedly used as representatives for several times [sic].”
According to a report of the ORI’s findings to be published in the Federal Register tomorrow, the paper, “Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing, published earlier this year in the Proceedings of the National Academy of Sciences (PNAS): Read the rest of this entry »
The liver is the only internal organ that can regenerate. So perhaps it shouldn’t be surprising that Egyptian researchers tried to publish the same paper about liver ischemia twice in different journals. They succeeded — for a little while, at least.
The Journal of Molecular Histology is retracting the second of the articles to appear. Titled “Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia–reperfusion injury in rats,” (which is still available online) it was published in 2011 by Vivian Boshra and Amal M. Moustafa of Mansoura University.
Trouble was, in 2011 Moustafa and Boshra, in that order, had also published “Effect of fenofibrate on the experimentally induced hepatic ischemia/reperfusion injury in rats: biochemical, light, and electron microscopic studies” in the Egyptian Journal of Histology (link to pdf).
That, as we know, is not done.
Pharmaceutical Biology has retracted a 2012 paper by a group of liver researchers from China after the discovery of an error that evidently invalidated the results in the paper.
The article, “Antifibrotic effects of protocatechuic aldehyde on experimental liver fibrosis,” purported to show that
protocatechuic aldehyde, the major degradation of phenolic acids … has potentially conferring antifibrogenic effects.
The group was forced to retract a Journal of Gastrointestinal and Liver Diseases paper in March. That retraction came alongside one in the New Zealand Journal of Medical Laboratory Science, whose editor had tipped JGLD editor Monica Acalovschi — who has taken a tough stance on duplication in her own journal, published in Romania — off to the duplication. Acalovschi, in turn, tipped off Biochemia Medica, the journal of Croatian Society of Medical Biochemistry and Laboratory Medicine, which has now retracted a 2009 paper by the group.
At issue was a 2011 paper on a biomarker for liver cancer by a group of Turkish authors who plagiarized from the work of others.
Here’s the notice for the article, titled “Diagnostic and Prognostic Validity of Golgi Protein 73 in Hepatocellular Carcinoma“: Read the rest of this entry »
A retraction notice in the Journal of Gastrointestinal and Liver Diseases — which bills itself as the “Official Journal of the Romanian Societies of Gastroenterology” — explains what happened: Read the rest of this entry »